

Title:

Esophageal stent dysfunction: unclogging the Red Sea

Authors:

Raquel R. Mendes, Pedro C. Figueiredo

DOI: 10.17235/reed.2024.10554/2024 Link: <u>PubMed (Epub ahead of print)</u>

Please cite this article as:

Mendes Raquel R., Figueiredo Pedro C.. Esophageal stent dysfunction: unclogging the Red Sea. Rev Esp Enferm Dig 2024. doi: 10.17235/reed.2024.10554/2024.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Esophageal stent dysfunction: unclogging the Red Sea

Raquel R. Mendes¹, Pedro C. Figueiredo¹

Author's institution

¹Gastroenterology Department, Unidade Local de Saúde de Lisboa Ocidental

Corresponding author's contact information

Raquel Rodrigues Mendes

Gastroenterology Department, Unidade Local de Saúde de Lisboa Ocidental

Rua da Junqueira 126, 1349-019 Lisbon, Portugal

raquelrmendes@gmail.com

Conflicts of interest

The authors disclose no conflicts of interest.

Keywords: Esophageal neoplasia. Palliative stenting. Stent dysfunction. Bleeding. Complete dysphagia.

Dear Editor,

Self-expandable metal stents (SEMS) have been widely used for the palliation of esophageal malignant dysphagia [1] [2]. Stent-related dysphagia is frequent and should raise the suspicion of stent migration, tumor ingrowth or overgrowth [1] [3] [4]. In addition, bleeding has been reported in nearly 7% of patients [2] [3] [4]. Nonetheless, this is the first case report of a complete stent obstruction by abundant blood clot formation.

The authors present a 76-year-old male with severe ischemic heart disease and atrial fibrillation, requiring cardiac resynchronization therapy defibrillator and anticoagulation. After being diagnosed with metastasized squamous cell mid-esophageal cancer, he was proposed for chemotherapy and palliative esophageal stenting.

According to protocol, following 3-day suspension of apixaban, a partially covered SEMS (23x100 mm) was successfully deployed across the ulcerated circumferential neoplasia at



26-33 cm from the incisors, under fluoroscopy and endoscopy guidance. After a 48h surveillance and radiological confirmation of the stent's expansion and position, anticoagulation was reintroduced, and the patient was discharged home on a soft diet.

One week later, he was readmitted to the emergency department with complaints of acute complete dysphagia. He confirmed diet adherence, and denied thoracic or abdominal pain, hematemesis or melaena, dyspnea or other neurological symptoms.

An X-ray confirmed adequate stent positioning. Upper endoscopy showed abundant blood clots fully occluding the stent's lumen, which were carefully pushed to the stomach, without intercurrences (Fig. 1A-B). Subsequent inspection confirmed stent expansion, and absence of migration or tumor in/overgrowth (Fig. 1C).

After discussion with the cardiology department, anticoagulation was temporally discontinued. Blood work showed only mild anemia, with normal platelet count and coagulation. No blood transfusion or hydroelectrolytic correction was required. In a 3-months follow-up, low-dose anticoagulation was carefully resumed, without recurrence of dysphagia, gastrointestinal hemorrhage, nor cardiovascular events.

Esophageal stent dysfunction is common and has been associated with several entities. Tumor friability and bleeding are recognized, however the clinical presentation with acute complete dysphagia without overt hemorrhage is uncharacteristic [1] [3] [4]. Additionally, recommendations on the adequate management of anticoagulation in this context are weak and an individualized care balancing the risks of hemorrhage versus cardiovascular thrombosis is crucial, specifically regarding this patient's medical history [4] [5].

References

- [1] Rodrigues-Pinto, E., Pereira, P., Baron, T. H., & Macedo, G. (2018). Self-expandable metal stents are a valid option in long-term survivors of advanced esophageal cancer. *Revista Española de Enfermedades Digestivas*, 110(8), 500-504.
- [2] Spaander, M. C., van der Bogt, R. D., Baron, T. H., Albers, D., Blero, D., de Ceglie, A., et al. (2021). Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline–Update 2021. *Endoscopy*, 53(07), 751-762.
- [3] Kumar, S., Bahdi, F., Emelogu, I. K., Yu, A. C., Coronel, M., Ge, P. S., et al. (2022). How much progress have we made?: a 20-year experience regarding esophageal stents for the palliation of malignant dysphagia. *Diseases of the Esophagus*, 35(6), doab085.
- [4] Reijm, A. N., Didden, P., Schelling, S. J., Siersema, P. D., Bruno, M. J., & Spaander, M. C. (2019). Self-expandable metal stent placement for malignant esophageal strictures—changes in clinical outcomes over time. *Endoscopy*, 51(01), 18-29.



[5] Veitch, A. M., Radaelli, F., Alikhan, R., Dumonceau, J. M., Eaton, D., Jerrome, J., et al. (2021). Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. *Endoscopy*, 53(09), 947-969.






Fig. 1. A-B Blood clots occluding the self-expandable partially covered metal stent. **C** Adequately expanded esophageal stent with no evidence of tumor ingrowth.

